Black Rock Inc. Vyne Therapeutics Inc. Transaction History

Black Rock Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.12 - $4.91 $177 - $7,266	-1,480 Reduced 0.17%	885,833 $132,000
Q3 2022 Nov 14, 2022	SELL	$0.24 - $4.27 $551 - $9,803	-2,296 Reduced 0.26%	887,313 $197,000
Q2 2022 Aug 12, 2022	SELL	$0.37 - $0.71 $41,804 - $80,219	-112,985 Reduced 11.27%	889,609 $346,000
Q1 2022 May 12, 2022	SELL	$0.5 - $1.15 $2,379 - $5,472	-4,759 Reduced 0.47%	1,002,594 $652,000
Q4 2021 Feb 10, 2022	SELL	$0.91 - $1.5 $27,225 - $44,877	-29,918 Reduced 2.88%	1,007,353 $1.03 Million
Q3 2021 Nov 09, 2021	SELL	$1.39 - $3.47 $564 - $1,408	-406 Reduced 0.04%	1,037,271 $1.44 Million
Q2 2021 Aug 11, 2021	BUY	$3.24 - $6.92 $3.36 Million - $7.18 Million	1,037,677 New	1,037,677 $3.64 Million

36.5K

Ticker VYNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,005,600
Market Cap $176M
Description
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, whi...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.